{"id":1021242,"date":"2026-11-16T08:13:44","date_gmt":"2026-11-16T13:13:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/"},"modified":"2026-11-16T08:13:44","modified_gmt":"2026-11-16T13:13:44","slug":"clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/","title":{"rendered":"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Vancouver, Canada, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212;  Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (\u201cAUD\u201d), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I\/IIa clinical trial evaluating CMND-100.<\/p>\n<p>The completion of patient enrollment for Part C marks another important milestone in Clearmind\u2019s clinical development program and reflects the continued strong execution of its Phase I\/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability data from Part A in healthy volunteers.<\/p>\n<p>Part C is a randomized, double-blind, placebo-controlled multiple-dose study designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100. The trial is being conducted at premier clinical research sites across the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.<\/p>\n<p>\u201cThe successful completion of Part C enrollment demonstrates the continued momentum of our CMND-100 program and represents another important milestone for Clearmind,\u201d said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. \u201cThe data generated in this cohort is expected to further enhance our understanding of CMND-100\u2019s safety, tolerability, and pharmacokinetic profile to help support the advancement of our proprietary non-hallucinogenic treatment candidate toward future development milestones.\u201d<\/p>\n<p>\n        <b>About Clearmind Medicine Inc.<\/p>\n<p><\/b>Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.<\/p>\n<p>The Company\u2019s intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.<\/p>\n<p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#8220;CMND.&#8221;<\/p>\n<p>For further information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Eu-norF-DIASE-3XoL6NXTvt26m-4Jvie-GgwTAYZ73YFPZsFybbD2yD-etLqofqd9RTQn8u0UuOBT_lnp1PUO1Vtbb7HIUKfDDtjQq2Af_qSoHTV3zK6ln7zYMT7uUY\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.clearmindmedicine.com<\/a>\u00a0or contact:<\/p>\n<p>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=11V_VbJ3BBamREXrY2GvsCdvd-BqsuV99i4GHXEztH8_zyKqkedOtTKHB9gnoNdUWPOo9qDhwpq8vRn-493vPcKfbQVZy8tXeUDtmmFm2MdiA47RkNcTieAsTloYG-fO\" rel=\"nofollow\" target=\"_blank\">invest@clearmindmedicine.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dEqDcqobCjjP3jJZ_WsJqjFvT4qaPQAwzetcNSuQFY1DyFhBt0IbsrCm0DMWwJR1cV4rEOpGS7rsKMPBG1b01ThQ53wXJa-4vtgHYz_9nSUha2z7hTp6aSq48br-B_Az\" rel=\"nofollow\" target=\"_blank\">www.Clearmindmedicine.com<\/a><\/p>\n<p>\n        <b>Forward-Looking Statements:<\/b>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated data from Part C of the Phase I\/IIa clinical trial, the potential for such data to further inform the Company\u2019s understanding of CMND-100\u2019s safety, tolerability and pharmacokinetic profile, and the continued clinical development and advancement of CMND-100 toward future development milestones. Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmZhZjUwNTYtNzhhNy00NGZhLWFhOWQtNTA2NTMzNWQyNDM5LTUwMDA4NjkzNC0yMDI2LTExLTE2LWVu\/tiny\/Clearmind-Medicine-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (\u201cAUD\u201d), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I\/IIa clinical trial evaluating CMND-100. The completion of patient enrollment for Part C marks another important milestone in Clearmind\u2019s clinical development program and reflects the continued strong execution of its Phase I\/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021242","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (\u201cAUD\u201d), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I\/IIa clinical trial evaluating CMND-100. The completion of patient enrollment for Part C marks another important milestone in Clearmind\u2019s clinical development program and reflects the continued strong execution of its Phase I\/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability &hellip; Continue reading &quot;Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T13:13:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\\\/IIa Trial, Marking Key Clinical Milestone\",\"datePublished\":\"2026-11-16T13:13:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/\"},\"wordCount\":775,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/\",\"name\":\"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\\\/IIa Trial, Marking Key Clinical Milestone - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==\",\"datePublished\":\"2026-11-16T13:13:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\\\/IIa Trial, Marking Key Clinical Milestone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/","og_locale":"en_US","og_type":"article","og_title":"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone - Market Newsdesk","og_description":"Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (\u201cAUD\u201d), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I\/IIa clinical trial evaluating CMND-100. The completion of patient enrollment for Part C marks another important milestone in Clearmind\u2019s clinical development program and reflects the continued strong execution of its Phase I\/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability &hellip; Continue reading \"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T13:13:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone","datePublished":"2026-11-16T13:13:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/"},"wordCount":775,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/","name":"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==","datePublished":"2026-11-16T13:13:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI4MSM3OTY3ODE5IzUwMDA4NjkzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-clinical-milestone\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I\/IIa Trial, Marking Key Clinical Milestone"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021242"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021242\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}